The course covers the rapidly evolving landscape of therapies used to treat cancer. This included chemotherapy, radiotherapy, targeted drugs, immunotherapies and biological therapies such as monoclonal antibodies. The course is delivered by lecturers who are all directly involved in the development of new cancer therapies who can deliver in depth insights into the latest advances in this area. Some have also been involved in developing these through to clinical trials and forming biotechnology spinout companies.
The course runs in 12x2 hour teaching sessions. Each consists of a mix of lectures, discussion and seminars. Seminars are interactive, reinforcing lecture content and providing examples of concepts raised in lectures.
During seminars, original research papers are presented by individual students. Seminar papers are carefully chosen by lecturers to emphasise important teaching points and provide demonstrative examples of selected cancer therapies (clinical and experimental). There is ample opportunity to discuss both lecture content and original research presented during seminars.
In the group seminar assignment students will be presented a scenario for the development of a potential new anti-cancer drug. They will work together in teams as if they were a startup biotech company to produce a clinical development plan for this drug. They will present this potential "investors" (lecturers with startup company experience) to seek the funding they need to take this drug through to FDA approval. This assignment will build transferable skills useful in industry.
Two 1500-word essays on a topic covering development of new cancer therapies. Essay topics are provided at the start of a semester and are independent of lectures. You will need to commit an independent study time to find literature in this area, synthesise and evaluate information from multiple research papers, including from other disciplines, recognise patterns and controversies in the field, draw conclusions about the potential for clinical translation, critique and summarise implications for both future research and clinical applications and also understand the realities of commercial development of new drugs. The aim of an essay is to stimulate your interest and critical thinking in understanding the process of developing new cancer therapies.
This course provides strong foundation for Honours, Masters or PhD in any area of cancer research or students interested in development of new cancer drugs. The focus is on biological underpinnings of anti-cancer therapies but we also have pharmacy and bioengineering students, medical laboratory scientists, nurses and other interdisciplinary students (including from the bioscience enterprise programme and those interested in the biotech industry) regularly taking this course.
If you have a strong interest in cancer biology, you may wish to combine MedSCi 713 with MedSci 714 (Advanced Cancer Biology), but this is not required.